Table 2. Summary of Lipid-Lowering Studies in HIV

AGENT TC TG HDL LDL

Pravastatin (1) (n=15) -1.23 mg/dL -0.31 mg/dL + 0.06 mg/dL -1.2 mg/dL
Pravastatin (6) (n=86 -41 mg/dL -27 mg/dL No change -30 mg/dL
Atorvastatin (2) (n=10) -19% -21%
Gemifibrozil (2) (n=25) -32% -57%
Gemifibrozil (4) (n=8) No change -83%
Fibtrates (3) (n=66) -22% -41%
Statins (3) (n=37) -25% -35%
Prav + Feno (6) (n=130) -16% -38% +16% -10%
Atorv + Gem (2) (n=19) -30% -60%
Fenofibrate (5) (n=13) -6.6% -45.7%
Fenofibrate (6) (n=88) -15 mg/dL -118 mg/dL +4 mg/dL +13 mg/dL

TC=total cholesterol; TG=triglycerides. (1)Moyle et al. AIDS 2001; 15:1503-8. (2) Henry et al. Lancet 1998; 352:1031-32. (3) Calza et al. AIDS 2003; 17:851-9. (4) Hewitt et al. AIDS 1999; 13:868-9. (5) Caramelli et al. J Infect Dis 2001; 5:332-8. (6) Aberg JA et al. 40th IDSA, 2002. Abstract 26.